Resources Here you can find resources to download and access related to Soliris® for the treatment of NMOSD in adult patients who are AQP4 antibody-postive with a relapsing course of the disease.
Please click the links below to be redirected to a third-party website, where you can access and find more information on these selected publications.
Alexion is not the copyright holder of either the journal or the articles – such copyright(s) is/are held by the publisher(s) and/or the author(s) of the journal and/or article as appropriate. Alexion has provided the weblinks to the full article(s) merely to assist the reader and on the basis that the relevant article(s) is/are either available as ‘open access’ or via a subscription service which the reader may already subscribe to. Alexion assumes no responsibility for ascertaining if the reader has appropriate copyright licence for use of the relevant article and Alexion makes no attempt to provide any licence or permission to the reader – all such permissions and ownership rest exclusively with their owners.
Healthcare professionals are asked to report any suspected adverse reactions. Please report any adverse reactions via your national reporting system. Adverse events should also be reported to Alexion pharmaceuticals by contacting: https://contactazmedical.astrazeneca.com
SOLIRIS® (eculizumab) EU Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/soliris-epar-product-information_en.pdf. Last accessed: November 2023.
advance I am a healthcare professional registered in the EU I am not a
healthcare professional